Rotonium will present at the “Quantum Computing in Life Sciences” conference in Milan on April 16, 2026, outlining strategies for integrating quantum computing into pharmaceutical research and development. The event will gather leaders from medicine, data science, and industry to discuss how quantum technologies, particularly when combined with artificial intelligence and machine learning, can accelerate drug discovery and personalize therapies. Rotonium CEO Roberto Siagri is scheduled to discuss the benefits of photonic quantum accelerators for molecule development and genome analysis, focusing on solutions designed for integration into hybrid computing workflows, from industrial workstations to scaling toward private data centers. This participation signals a growing trend of industrial investment in quantum computing as companies explore its potential to shorten time-to-market and improve outcomes in a rapidly evolving pharmaceutical landscape.
“Quantum Computing in Life Sciences” Milan Conference, April 2026
The conference aims to dissect the practical applications of quantum computing across the entire drug development pipeline, from initial research and development of novel molecules to the implementation of artificial intelligence and digital twins for highly personalized therapeutic simulations. Experts anticipate discussions will also cover the ongoing digitalization of pharmaceutical manufacturing processes and strategies to expedite the delivery of new therapies to market, particularly within competitive landscapes. The increasing integration of quantum computing into strategic industrial planning, coupled with substantial investment, particularly when combined with AI and machine learning, is driving the need for cross-disciplinary collaboration. Organizers expect attendees from medicine, pharmaceutical companies, academic institutions, data science, quantum platform providers, and venture capital firms to converge and share insights into current advancements and potential future partnerships.
Rotonium’s Photonic Quantum Accelerators for Molecule & Genome Analysis
The conference will gather a diverse group of stakeholders, including pharmaceutical companies, academics, and venture capitalists, to discuss current progress and future possibilities within the field, particularly the increasing synergy between quantum computing, artificial intelligence, and machine learning. These accelerators are designed to function at room temperature and integrate into a range of settings, from individual workstations to larger private data centers, addressing a key challenge in wider quantum adoption. According to Rotonium, these compact systems offer a pathway to speed up critical processes within the pharmaceutical industry, potentially reducing time-to-market for new therapies in a rapidly evolving landscape. This participation reflects a broader trend of escalating industrial investment in quantum computing, driven by its promise to revolutionize areas like drug discovery and personalized healthcare; the conference aims to showcase how these technologies can translate into tangible benefits for patients and advance quantum-AI development.
During the program, Roberto Siagri (CEO, Rotonium) will deliver a talk on the advantages of photonic quantum accelerators for molecule development and genome analysis, highlighting compact, room-temperature solutions designed for integration into hybrid computing workflows-from industrial workstations to scaling toward private data centers.
